In the BioHarmony Drug Report Database

"Preview" Icon

Bempedoic acid

Nexletol, Nilemdo (bempedoic acid) is a small molecule pharmaceutical. Bempedoic acid was first approved as Nexletol on 2020-02-21. It is used to treat atherosclerosis and hyperlipoproteinemia type II in the USA. It has been approved in Europe to treat dyslipidemias and hypercholesterolemia. The pharmaceutical is active against ATP-citrate synthase. Nexletol’s patents are valid until 2025-12-03 (FDA).

 

Trade Name

 

Nilemdo
 

Common Name

 

bempedoic acid
 

ChEMBL ID

 

CHEMBL3545313
 

Indication

 

atherosclerosis, dyslipidemias, hypercholesterolemia, hyperlipoproteinemia type ii
 

Drug Class

 

Image (chem structure or protein)

Bempedoic acid structure rendering